Literature DB >> 17347914

International Morquio A Registry: clinical manifestation and natural course of Morquio A disease.

A M Montaño1, S Tomatsu, G S Gottesman, M Smith, T Orii.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA; Morquio A disease) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase. The natural history of this disease is incompletely understood. To study which variables influence the clinical outcome, we conducted a study in which MPS IVA patients were asked to fill out a questionnaire with inquiries regarding family history, diagnosis, signs and symptoms, height, weight, surgical history, physical activity, and general complaints. A total of 326 patients (172 male, 154 female) from 42 countries enrolled in the Morquio A Registry programme. The mean age of patients enrolled was 14.9 years for males and 19.1 years for females, with a wide range of 1-73 years. Sixty-four per cent of the patients were under 18 years. Initial symptoms were recognized between 1 and 3 years of age (mean age 2.1 years) and mean age at diagnosis for the patients was 4.7 years. A progressive skeletal dysplasia was commonly observed among the MPS IVA patients. Fifty per cent of patients underwent surgical operations to improve their quality of life. The most frequent surgical sites include neck (51%), ear (33%), leg (26%) and hip (25%). The birth length for affected males and females was 52.2 +/- 4.7 cm and 52.2 +/- 4.5 cm, respectively. The final adult height for affected males and females was 122.5 +/- 22.5 cm and 116.5 +/- 20.5 cm, respectively. The results of this study provide a reference for assessment of efficacy for studies of novel therapies.

Entities:  

Mesh:

Year:  2007        PMID: 17347914     DOI: 10.1007/s10545-007-0529-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  24 in total

1.  Morquio disease: isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  S Tomatsu; S Fukuda; M Masue; K Sukegawa; T Fukao; A Yamagishi; T Hori; H Iwata; T Ogawa; Y Nakashima
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

2.  Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  Shunji Tomatsu; Monica Gutierrez; Tatsuo Nishioka; Masamichi Yamada; Mana Yamada; Yasuhiro Tosaka; Jeffrey H Grubb; Adriana M Montaño; Matheus B Vieira; Georgeta G Trandafirescu; Olga M Peña; Seiji Yamaguchi; Koji O Orii; Tadao Orii; Akihiko Noguchi; Leticia Laybauer
Journal:  Hum Mol Genet       Date:  2005-10-11       Impact factor: 6.150

3.  The enzymic defects in Morquio and Maroteaux-Lamy syndrome.

Authors:  A Dorfman; B Arbogast; R Matalon
Journal:  Adv Exp Med Biol       Date:  1976       Impact factor: 2.622

4.  Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A).

Authors:  Shunji Tomatsu; Adriana M Montaño; Tatsuo Nishioka; Monica A Gutierrez; Olga M Peña; Georgeta G Tranda Firescu; Patricia Lopez; Seiji Yamaguchi; Akihiko Noguchi; Tadao Orii
Journal:  Hum Mutat       Date:  2005-12       Impact factor: 4.878

5.  A novel common missense mutation G301C in the N-acetylgalactosamine-6-sulfate sulfatase gene in mucopolysaccharidosis IVA.

Authors:  Z Kato; S Fukuda; S Tomatsu; H Vega; T Yasunaga; A Yamagishi; N Yamada; A Valencia; L A Barrera; K Sukegawa; T Orii; N Kondo
Journal:  Hum Genet       Date:  1997-11       Impact factor: 4.132

6.  The mouse N-acetylgalactosamine-6-sulfate sulfatase (Galns) gene: cDNA isolation, genomic characterization, chromosomal assignment and analysis of the 5'-flanking region.

Authors:  A M Montaño; A Yamagishi; S Tomatsu; S Fukuda; N G Copeland; K E Orii; K Isogai; N Yamada; Z I Kato; N A Jenkins; D J Gilbert; K Sukegawa; T Orii; N Kondo
Journal:  Biochim Biophys Acta       Date:  2000-03-17

7.  Molecular heterogeneity in mucopolysaccharidosis IVA in Australia and Northern Ireland: nine novel mutations including T312S, a common allele that confers a mild phenotype.

Authors:  N Yamada; S Fukuda; S Tomatsu; V Muller; J J Hopwood; J Nelson; Z Kato; A Yamagishi; K Sukegawa; N Kondo; T Orii
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

8.  Mucopolysaccharidosis IV A: molecular cloning of the human N-acetylgalactosamine-6-sulfatase gene (GALNS) and analysis of the 5'-flanking region.

Authors:  Y Nakashima; S Tomatsu; T Hori; S Fukuda; K Sukegawa; N Kondo; Y Suzuki; N Shimozawa; T Orii
Journal:  Genomics       Date:  1994-03-01       Impact factor: 5.736

9.  Mucopolysaccharidosis type IVA: common double deletion in the N-acetylgalactosamine-6-sulfatase gene (GALNS).

Authors:  T Hori; S Tomatsu; Y Nakashima; A Uchiyama; S Fukuda; K Sukegawa; N Shimozawa; Y Suzuki; N Kondo; T Horiuchi
Journal:  Genomics       Date:  1995-04-10       Impact factor: 5.736

10.  Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease.

Authors:  Shunji Tomatsu; Koji O Orii; Carole Vogler; Jun Nakayama; Beth Levy; Jeffrey H Grubb; Monica A Gutierrez; Soomin Shim; Seiji Yamaguchi; Tatsuo Nishioka; Adriana Maria Montano; Akihiko Noguchi; Tadao Orii; Naomi Kondo; William S Sly
Journal:  Hum Mol Genet       Date:  2003-10-28       Impact factor: 6.150

View more
  124 in total

1.  Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII.

Authors:  Tsutomu Shimada; Shunji Tomatsu; Eriko Yasuda; Robert W Mason; William G Mackenzie; Yuniko Shibata; Francyne Kubaski; Roberto Giugliani; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii
Journal:  JIMD Rep       Date:  2014-05-22

Review 2.  Growth impairment in mucopolysaccharidoses.

Authors:  Melodie Melbouci; Robert W Mason; Yasuyuki Suzuki; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-03-16       Impact factor: 4.797

3.  An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants.

Authors:  R L Richesson; H S Lee; D Cuthbertson; J Lloyd; K Young; J P Krischer
Journal:  Contemp Clin Trials       Date:  2008-09-07       Impact factor: 2.226

4.  Spondyloepiphyseal dysplasias and bilateral legg-calvé-perthes disease: diagnostic considerations for mucopolysaccharidoses.

Authors:  Nancy J Mendelsohn; Timothy Wood; Rebecca A Olson; Renee Temme; Susan Hale; Haoyue Zhang; Lisa Read; Klane K White
Journal:  JIMD Rep       Date:  2013-05-09

5.  Subjective and Objective Assessment of Hand Function in Mucopolysaccharidosis IVa Patients.

Authors:  Riffat Aslam; Annelotte C M van Bommel; Christian J Hendriksz; Andrea Jester
Journal:  JIMD Rep       Date:  2012-10-13

6.  Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  A M Montaño; K Sukegawa; Z Kato; R Carrozzo; P Di Natale; E Christensen; K O Orii; T Orii; N Kondo; S Tomatsu
Journal:  J Inherit Metab Dis       Date:  2007-09-17       Impact factor: 4.982

7.  Development of a Scoring System to Evaluate the Severity of Craniocervical Spinal Cord Compression in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome).

Authors:  Christian Möllmann; Christian G Lampe; Wibke Müller-Forell; Maurizio Scarpa; Paul Harmatz; Manfred Schwarz; Michael Beck; Christina Lampe
Journal:  JIMD Rep       Date:  2013-04-12

8.  Combined spinal arthrodesis with instrumentation for the management of progressive thoracolumbar kyphosis in children with mucopolysaccharidosis.

Authors:  Enrique Garrido; Félix Tomé-Bermejo; Christopher I Adams
Journal:  Eur Spine J       Date:  2014-01-28       Impact factor: 3.134

9.  Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  Carlos J Alméciga-Díaz; Maria A Rueda-Paramo; Angela J Espejo; Olga Y Echeverri; Adriana Montaño; Shunji Tomatsu; Luis A Barrera
Journal:  Mol Biol Rep       Date:  2008-11-07       Impact factor: 2.316

Review 10.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.